compounded semaglutide fda shortage resolved feb 21 2025 declaratory order february The FDA has issued a warning to Semaglutide & Tirzepatide 2025: – FDA: Ozempic and Wegovy drug – FDA Ends Compounded GLP-1s: What

These peptides are: Prescribed by licensed physicians after comprehensive evaluation Sourced from FDA-registered facilities with rigorous quality controls Subject to purity testing and certificate of analysis verification Administered according to evidence-based protocols with appropriate monitoring Covered by professional liability insurance when used appropriately This stands in stark contrast to the gray and black market peptides flooding online forums, fitness communities, and even some wellness clinics. Understanding this distinction isnt just about compliance its about safety, efficacy, and protecting your health

As with any evolving treatment landscape, the best results come from careful dosing, ongoing education and staying current on regulatory developments

The peptide enhances healing but cannot override continued tissue damage from excessive mechanical stress

11.1% of participants said they used GLP-1s for more than 18 months

eLife (2017)

PMID: 11045725